(RTTNews) - Exact Sciences Corp. (EXAS) Monday has introduced Cologuard Plus, an FDA-approved noninvasive colorectal cancer - CRC screening test for average-risk adults aged 45 and older. It offers 95 ...
Colon cancer is the number two cancer killer in men and women who do not smoke. (Breast cancer is number one in women, while prostate cancer is number one in men). For decades now, scientists and ...
If a blue-and-white box has arrived at your door, you’re not alone. Millions of adults across the U.S. now receive a use-at-home colorectal cancer screening test through their health insurance or ...
Cologuard is based on ColoSure in that Cologuard is also based on detecting DNA changes in the stool, Markowitz said. "We were the first to discover that we could detect colorectal cancer in ...
Although Exact Sciences’ Cologuard completed its 2 millionth test, the multitarget stool DNA test remains a topic of contention in the gastroenterology space. Touting 92 percent sensitivity and 87 ...
Cologuard does not require dietary restrictions or bowel preparation prior to taking the test. The patient then collects a stool sample in the Cologuard collection kit and sends the kit back in a ...
MADISON, Wis., July 31, 2025--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc ...
Anne grew up in a small farm town in southeast Nebraska, where her upbringing was filled with lessons on problem solving, teamwork and the importance of giving back. These qualities have carried her ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results